Lipid Genomics has a mission to develop diagnostics and therapeutics targeted at patients with acute and chronic inflammatory diseases, such as acute immunotoxicity in oncology and chronic atherosclerotic heart disease.
Dr. Rodriguez is a board certified endocrinologist with expertise in cholesterol disorders and diabetes mellitus. While a full-time faculty member of the Johns Hopkins University School
of Medicine in Baltimore, Maryland USA, Dr. Rodriguez developed molecular diagnostic tests to identify people with SCARB1 genetic variations that might be at risk for heart disease
in men and women and infertility in women.
In October 2012 Iverson Genetic Diagnostics publicly announced a licensing agreement with Johns Hopkins for the SCARB1 molecular diagnostic tests, and these
tests are now available for health care providers to correctly diagnose patients.
Lipid Genomics is located in Farmington, Connecticut and it currently has three product lines under development. All product development supports the mission to identify therapeutics and
diagnostics targeted towards patients with acute and chronic inflammatory diseases, including patients with genetic cholesterol disorders such as SCARB1 deficiency.
